SOURCE: BioMedReports


July 19, 2011 15:54 ET

Report: TapImmune Investors Expecting News About Key Developments

LOS ANGELES, CA--(Marketwire - Jul 19, 2011) - A dispatch trade report about TapImmune (OTCBB: TPIV) informs readers at BioMedReports that biotech analysts are anticipating good news on several fronts for the company's ongoing collaborative research programs.

Over the last two years, the emerging biotech firm with a platform that shows promising potential in treating both cancers and infectious diseases has been working diligently on finding partners that they can work closely with to form mutually beneficial collaborative arrangements. In February of last year, the company announced a collaboration intent with Aeras Global TB Foundation that may finally be set to come into play.

Aeras is easily one of the foremost non-profit organizations developing new approaches for TB vaccines and is dedicated to the development of effective TB vaccine regimens that will prevent tuberculosis in all age groups and will be affordable, available and adopted worldwide. Aeras is funded primarily by government aid agencies and some very big private foundations -- including the Bill & Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases. A forthcoming collaboration would certainly help validate and call attention to TapImmune's innovative cancer and infectious disease targeting platform.

TapImmune plans to evaluate its TAP technology for improving the efficacy of vaccines designed to combat a range of additional viral threats in the biodefense and infectious disease field. To expand its technology platform, TapImmune also plans to enter additional technology collaborations for the development of DNA plasmid expression vectors that can deliver TAP genes into target cells.

According to the special report, the company also continues to anticipate news about the IND for the first Phase I study in their program to develop a vaccine against HER-2/neu breast cancer. The technology entering the clinic targets a novel set of HER-2/neu antigens discovered in breast cancer patients with pre-existent immunity to these antigens (Clinical Cancer Research 16[3]:825-34, 2010). This technology complements TapImmune's TAP technology that is envisioned as part of a final vaccine product. This technology is currently completing preclinical development.

Currently, Herceptin® (trastuzumab: an intravenously delivered monoclonal antibody) is used in the treatment of HER-2/neu breast cancer. Sales of this product in 2009 were approximately US$5 billion (source: Roche AG's Pharmaceutical Division). TapImmune's vaccine approach has the potential to treat a broader HER-2/neu positive clinical population, and the market potential for their cancer vaccine is significant.

As we reported in mid June, TPIV filed an SEC form 8-K, Regulation FD Disclosure which quietly revealed that an investigative new drug application ("IND") for a Phase I clinical trial on a set of HER-2/neu breast cancer antigens that the company has the exclusive option to license after Phase I studies had been filed. News about whether the IND has been accepted by the FDA is expected any day.

A special report on the significance of these important developments and what they could mean to investors of this company is available now at:

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades can go to:

News developments and live healthcare sector updates are available constantly via twitter at:


BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556